These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

186 related articles for article (PubMed ID: 2936872)

  • 1. Gonadotropin hormone-releasing hormone analogues: a new therapeutic approach for prostatic carcinoma.
    Eisenberger MA; O'Dwyer PJ; Friedman MA
    J Clin Oncol; 1986 Mar; 4(3):414-24. PubMed ID: 2936872
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Hormone therapy of prostatic bone metastases.
    Huben RP
    Adv Exp Med Biol; 1992; 324():305-16. PubMed ID: 1492625
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Leuprolide: a gonadotropin-releasing hormone analog for the palliative treatment of prostatic cancer.
    Wojciechowski NJ; Carter CA; Skoutakis VA; Bess DT; Falbe WJ; Mickle TR
    Drug Intell Clin Pharm; 1986 Oct; 20(10):746-51. PubMed ID: 2429815
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Clinical effects of gonadotropin-releasing hormone analogue in metastatic carcinoma of prostate.
    Smith JA; Glode LM; Wettlaufer JN; Stein BS; Glass AG; Max DT; Anbar D; Jagst CL; Murphy GP
    Urology; 1985 Feb; 25(2):106-14. PubMed ID: 3918369
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Luteinizing hormone-releasing hormone (LHRH) agonists for treatment of advanced prostatic carcinoma.
    Chodak GW
    Urology; 1989 May; 33(5 Suppl):42-4. PubMed ID: 2523610
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Management of metastatic prostatic cancer.
    Paulson DF
    Urology; 1985 Feb; 25(2 Suppl):49-52. PubMed ID: 3918376
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Treatment with different GnRH analogues in women: preliminary evidence for disparant effects on serum androgen concentrations.
    Rossmanith WG; Wirth U; Sasse V; Lauritzen C
    Horm Metab Res; 1991 Apr; 23(4):198-9. PubMed ID: 1831437
    [No Abstract]   [Full Text] [Related]  

  • 8. Recent developments in endocrine treatment of prostate cancer.
    Vogelzang NJ; Kennealey GT
    Cancer; 1992 Aug; 70(4 Suppl):966-76. PubMed ID: 1386283
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Gonadotropin-releasing hormone analogs and prostatic cancer.
    Swanson LJ; Seely JH; Garnick MB
    Crit Rev Oncol Hematol; 1988; 8(1):1-26. PubMed ID: 2964939
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Endocrine treatment of prostate cancer.
    Turkes AO; Griffiths K
    Prog Med Chem; 1989; 26():299-321. PubMed ID: 2532376
    [No Abstract]   [Full Text] [Related]  

  • 11. [Treatment of carcinoma of the prostate with analogs of LHRH].
    Rubio Herrera MA; Calle Fernández JR
    Rev Clin Esp; 1986 Nov; 179(8):407-11. PubMed ID: 2951782
    [No Abstract]   [Full Text] [Related]  

  • 12. Phase III studies in prostatic cancer with leuprolide acetate.
    Seely JH
    J Androl; 1987; 8(1):S23-6. PubMed ID: 3104263
    [No Abstract]   [Full Text] [Related]  

  • 13. Androgen suppression by a gonadotropin releasing hormone analogue in patients with metastatic carcinoma of the prostate.
    Smith JA
    J Urol; 1984 Jun; 131(6):1110-2. PubMed ID: 6427478
    [TBL] [Abstract][Full Text] [Related]  

  • 14. GnRH agonists: gonadorelin, leuprolide and nafarelin.
    Pace JN; Miller JL; Rose LI
    Am Fam Physician; 1991 Nov; 44(5):1777-82. PubMed ID: 1835275
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Newer methods of hormonal therapy for prostate cancer.
    Soloway MS
    Urology; 1984 Nov; 24(5 Suppl):30-8. PubMed ID: 6437034
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Zoladex in prostatic carcinoma].
    Di Silverio F; Serio M
    Drugs Exp Clin Res; 1990; 16 Suppl():19-29. PubMed ID: 2150501
    [No Abstract]   [Full Text] [Related]  

  • 17. Drug therapy of prostatic cancer.
    Huben RP; Perrapato SD
    Drugs Aging; 1991; 1(5):353-63. PubMed ID: 1838950
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Endocrine factors in the treatment of prostatic cancer.
    Pierrepoint CG; Turkes AO; Walker KJ; Harper ME; Wilson DW; Peeling WB; Griffiths K
    Prog Clin Biol Res; 1985; 185A():51-72. PubMed ID: 3162177
    [No Abstract]   [Full Text] [Related]  

  • 19. Goserelin. A review of its pharmacodynamic and pharmacokinetic properties, and clinical use in sex hormone-related conditions.
    Chrisp P; Goa KL
    Drugs; 1991 Feb; 41(2):254-88. PubMed ID: 1709853
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Luteinizing hormone-releasing hormone (LH-RH) analogs in treatment of prostatic cancer. Clinical perspective.
    Smith JA
    Urology; 1986 Jan; 27(1 Suppl):9-15. PubMed ID: 3079936
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.